Benjamin Saylor


Darolutamide Lowers Risk of Metastatic Progression in Nonmetastatic CRPC

June 7th 2022

Darolutamide significantly reduced the risk of metastatic progression and improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide Does Not Affect Cabazitaxel Systemic Exposure in mCRPC

June 7th 2022

Cabazitaxel can safely be combined with darolutamide in patients with metastatic castration-resistant prostate cancer.

177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel

June 5th 2022

177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities

Maintenance Avelumab Maintains Survival Benefit as First-Line Maintenance Across Subgroups in Advanced Urothelial Cancer

June 4th 2022

The addition of maintenance avelumab to best supportive care demonstrated improved outcomes for patients with advanced urothelial carcinoma including those who went on to receive second-line therapy.

Single-Agent Cabozantinib Stalls as Maintenance Therapy in Advanced Urothelial Cancer

June 4th 2022

Results of the ATLANTIS study do not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer.

Adjuvant Pembrolizumab Maintains DFS Benefit in High-Risk RCC

February 20th 2022

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

Darolutamide Maintains Efficacy in Patients with Comorbidities, Concomitant Medications in Nonmetastatic CRPC

February 18th 2022

The androgen receptor inhibitor darolutamide demonstrated continued efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have comorbidities or concomitant medications

Pembrolizumab/Olaparib Combo May Improve PSA Response Regardless of HRR Mutation Status in mCRPC

September 18th 2021

Pembrolizumab plus olaparib may improve prostate-specific antigen response rate in patients with metastatic castration-resistant prostate cancer regardless of homologous recombination repair mutation status.

Darolutamide Delays Time to Deterioration in HRQoL Related to Urinary and Bowel Symptoms in nmCRPC

September 12th 2021

Darolutamide was linked with a reduction in locally invasive procedures, delayed time to deterioration in health-related quality of life related to urinary and bowel symptoms in patients with nonmetastatic castration-resistant prostate cancer.

Addition of Abiraterone to ADT plus Docetaxel Yields Improvement in rPFS in De Novo mCSPC

June 9th 2021

Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.

Men With African Ancestry Less Likely to Receive Early Genomic Profiling in Prostate Cancer

June 8th 2021

Findings of a study examining comprehensive genomic profiling shed more light on disparities in prostate cancer care.

Pembrolizumab Plus Gemcitabine/Hypofractionated Radiotherapy Demonstrates Promising Efficacy in Muscle-Invasive Bladder Cancer

June 7th 2021

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer.

Antitumor Activity Demonstrated With Novel PSMA-Targeted Agent HPN424 in mCRPC

June 4th 2021

The tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager HPN424 demonstrated antitumor activity and was well tolerated in patients with metastatic castration-resistant prostate cancer.

Novel Combinations Under Study in Advanced RCC

April 12th 2021

The activity and safety of investigational combinations will be subject to study in patients with advanced clear cell renal cell carcinoma (ccRCC) as part of a phase 1b/2 umbrella platform trial.

Molecular Signatures Linked With Long-Term Response to Apalutamide in Nonmetastatic CRPC

February 13th 2021

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Apalutamide Demonstrates Sustained Survival Benefit in mCSPC

February 13th 2021

February 13, 2021 - Treatment with apalutamide plus androgen-deprivation therapy reduced the risk of death by 35% versus ADT alone in patients with metastatic castration-sensitive prostate cancer.

Crossover Minimally Impacts OS Benefit Achieved With Darolutamide in ARAMIS Trial

February 12th 2021

February 12, 2021 - Crossover from placebo to darolutamide appeared to have minimal impact on the overall survival benefit experienced by patients with nonmetastatic castration-resistant prostate cancer who were enrolled to the pivotal phase 3 ARAMIS trial.

Urothelial Cancer Treatment Combination Fails To Meet OS End Points

September 19th 2020

Neither monotherapy with durvalumab or combination treatment with durvalumab plus tremelimumab met co-primary end points of overall survival vs chemotherapy for the treatment of metastatic urothelial cancer.

Nivolumab/Ipilimumab Combo Shows Durable Benefit at 4 Years in Advanced RCC

September 19th 2020

The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.